Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Compass Therapeutics, Inc. CMPX NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
61/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$11.20
+105.9%

Compass Therapeutics, Inc. (CMPX) is a Biotechnology company in the Healthcare sector, currently trading at $5.44. It has a SharesGrow Score of 59/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is CMPX = $11 (+105.9% upside).

Valuation: CMPX trades at a trailing Price-to-Earnings (P/E) of -14.9 (S&P 500 average ~25).

Net income is $66M (loss), growing at -22.1%/yr. Net profit margin is 0% (thin). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $10M against $197M equity (Debt-to-Equity (D/E) ratio 0.05, conservative). Current ratio is 15.02 (strong liquidity). Debt-to-assets is 4.5%. Total assets: $220M.

Analyst outlook: 13 / 13 analysts rate CMPX as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 52/100 (Partial), Future 100/100 (Pass), Income ?/100 (Fail).

$11.20
▲ 105.88% Upside
Average Price Target
Based on 13 Wall Street analysts offering 12-month price targets for Compass Therapeutics, Inc., the average price target is $11.20, with a high forecast of $15.00, and a low forecast of $9.00.
Highest Price Target
$15.00
Average Price Target
$11.20
Lowest Price Target
$9.00

CMPX SharesGrow Score Overview

73/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 52/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CMPX

✓
VALUE Pass
100/100
CMPX trades at a trailing Price-to-Earnings (P/E) of -14.9 (S&P 500 average ~25). Forward PEG -2.8 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $11, implying +102.2% from the current price $5. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
CMPX: -100%/yr revenue is, -22.1%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet CMPX: Debt-to-Equity (D/E) ratio 0.05 (conservative), Current ratio is 15.02 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
52/100
CMPX: Gross margin is 100% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 52/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 13 / 13 analysts rate CMPX as buy (100%). Analyst consensus target is $11 (+102.2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.4-6.88
Volume3.51M
Avg Volume (30D)2.19M
Market Cap$752.28M
Beta (1Y)1.30
Share Statistics
EPS (TTM)-0.42
Shares Outstanding$157.7M
IPO Date2021-04-05
Employees35
CEOThomas J. Schuetz
Financial Highlights & Ratios
EBITDA$-72.84M
Net Income$-66.49M
Operating Income$-72.84M
Total Cash$208.91M
Total Debt$9.83M
Net Debt$-20.81M
Total Assets$219.59M
Price / Earnings (P/E)-13
Analyst Forecast
1Y Price Target$10.00
Target High$15.00
Target Low$9.00
Upside+83.8%
Rating ConsensusBuy
Analysts Covering13
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS20454B1044

Price Chart

Track all markets on TradingView
CMPX
Compass Therapeutics, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
1.40 52WK RANGE 6.88

People Also View

NAMS
NAMS
NewAmsterdam Pharma Company N.V.
$34.44
-4.99%
 GPCR
GPCR
Structure Therapeutics Inc.
$53.19
-1.95%
 IDYA
IDYA
IDEAYA Biosciences, Inc.
$32.35
-1.43%
 ELVN
ELVN
Enliven Therapeutics, Inc.
$44.85
+2.33%
 ANAB
ANAB
AnaptysBio, Inc.
$70.22
+2.17%
 TYRA
TYRA
Tyra Biosciences, Inc.
$35.27
-0.98%
 MLTX
MLTX
MoonLake Immunotherapeutics
$18.78
+1.90%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$17.50
-0.28%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message